Core Viewpoint - Tianxing Medical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International serving as joint sponsors [1] Company Summary - Tianxing Medical is the fourth largest provider of sports medicine equipment in China, with a market share of approximately 6.5%, and ranks first among domestic brands [1] - The company focuses on clinical solutions for sports medicine, offering products that include implants, active devices, consumables, and surgical tools, primarily for treating soft tissue injuries and sports rehabilitation in the shoulder, knee, and hip areas [1] - The company has a portfolio of 62 products, with 27 items certified as Class III medical devices, making it the company with the most certifications in the domestic sports medical industry; it has also received over 200 regulatory approvals overseas [1] - As of the end of 2024, Tianxing Medical's products have been adopted by over 3,000 hospitals, with cumulative sales exceeding 1.8 million units [1] Industry Summary - The Chinese sports medicine equipment market is still in its early development stage, with an expected compound annual growth rate (CAGR) of 16.5% from 2024 to 2030, indicating potential for increased market penetration by domestic providers [1] - The market is highly concentrated and dominated by international players, with the top five companies holding 59.3% of the market share; Tianxing Medical leads in the segments of surgical equipment, related consumables, and sports medicine implants among domestic brands [1]